Eli lilly and company
LLY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分名列前茅，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
LLY 近期報酬表現
1.19%
Eli lilly and company
6.23%
同產業平均
1.02%
S&P500
與 LLY 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NVO | Novo nordisk as | 4 分 | 4 分 | 4 分 | 2 分 | 5 分 | |
PFE | Pfizer inc | 3 分 | 2 分 | 2 分 | 2 分 | 5 分 | |
JNJ | Johnson & johnson | 2 分 | 2 分 | 1 分 | 3 分 | 5 分 | |
MRK | Merck & co. , inc. | 2 分 | 4 分 | 5 分 | 3 分 | 5 分 | |
ZTS | Zoetis inc | 5 分 | 3 分 | 4 分 | 3 分 | 3 分 |
- NVO Novo nordisk as價值 4 分趨勢 4 分波段 4 分籌碼 2 分股利 5 分查看更多
LLY 公司資訊
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.